Mizuno K, Koide T, Yoshimura M, Araie M
Department of Pharmacology, Tokyo Research Laboratories, Kowa Company, Ltd., 2-17-43 Noguchi-cho, Higashimurayama, Tokyo 189-0022, Japan.
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):688-94.
To investigate the effect of nipradilol, an alpha(1),beta-blocker with a nitric oxide donative action, on N:-methyl-D-aspartate (NMDA)-induced retinal damage in rats and to determine whether topically instilled nipradilol penetrates the ipsilateral posterior retina-choroid at pharmacologically active concentrations in rabbits.
To determine effects on NMDA-induced damage, drugs were injected alone or with NMDA into the vitreous of one eye, and cell loss in the ganglion cell layer (GCL) and thinning of the retinal neural cell layers were histologically evaluated. To evaluate posterior penetration, first, [(14)C]-nipradilol was instilled, and its tissue concentration was measured. Second, nipradilol or timolol was instilled, and their effects on intravitreal injection of endothelin-1-induced retinal artery contraction were compared, to evaluate whether a pharmacologically active level of nipradilol penetrates the inner limiting layer by topical application.
Intravitreous injection of NMDA reduced cell numbers in the GCL and the thickness of the inner plexiform layer (IPL) to 50.4% +/- 2.6% and 47.8% +/- 4.9% (n = 8) of control, respectively. Nipradilol alone had no effect. Coadministration of nipradilol with NMDA reduced cell numbers in the GCL and IPL thickness to 67.8% +/- 2.2% and 74.4% +/- 5.2% of control, respectively (P: < 0.05-0.01). Sodium nitroprusside, but not timolol or bunazosin, also significantly prevented the NMDA-induced reduction of cell numbers in the GCL and IPL thickness. Radioactivity of nipradilol was found in the ipsilateral posterior retina-choroid at 318.6 +/- 42.9 ng/g (n = 4), which was significantly higher than in the contralateral control (107.4 +/- 21.8 ng/g). Topical application of nipradilol, but not timolol, significantly suppressed the endothelin-1-induced contraction of the retinal artery (83.95% +/- 8.15% and 35.24% +/- 5.62% of baseline vessel diameter for nipradilol and timolol, respectively).
Nipradilol suppressed the NMDA-induced retinal damage in rats for which nitric oxide released from nipradilol may be responsible. Posterior penetration studies suggested that an effective concentration of nipradilol reached the posterior retina after topical application.
研究具有一氧化氮释放作用的α(1)、β受体阻滞剂尼普地洛对N-甲基-D-天冬氨酸(NMDA)诱导的大鼠视网膜损伤的影响,并确定局部滴注尼普地洛是否能在兔体内以药理活性浓度穿透同侧视网膜后极部脉络膜。
为确定对NMDA诱导损伤的影响,将药物单独或与NMDA注入一只眼的玻璃体,通过组织学评估神经节细胞层(GCL)中的细胞丢失及视网膜神经细胞层的变薄情况。为评估后极部穿透情况,首先,滴注[(14)C] - 尼普地洛,并测量其组织浓度。其次,滴注尼普地洛或噻吗洛尔,并比较它们对玻璃体内注射内皮素 - 1诱导的视网膜动脉收缩的影响,以评估局部应用时尼普地洛的药理活性水平是否能穿透内界膜。
玻璃体内注射NMDA使GCL中的细胞数量及内网状层(IPL)厚度分别降至对照的50.4%±2.6%和47.8%±4.9%(n = 8)。单独使用尼普地洛无作用。尼普地洛与NMDA联合给药使GCL中的细胞数量及IPL厚度分别降至对照的67.8%±2.2%和74.4%±5.2%(P < 0.05 - 0.01)。硝普钠可显著预防NMDA诱导的GCL中细胞数量减少及IPL厚度降低,而噻吗洛尔或布那唑嗪则无此作用。在同侧视网膜后极部脉络膜中发现尼普地洛的放射性为318.6±42.9 ng/g(n = 4),显著高于对侧对照(107.4±21.8 ng/g)。局部应用尼普地洛可显著抑制内皮素 - 1诱导的视网膜动脉收缩(尼普地洛和噻吗洛尔分别为基线血管直径的83.95%±8.15%和35.24%±5.62%)。
尼普地洛可抑制NMDA诱导的大鼠视网膜损伤,这可能与尼普地洛释放的一氧化氮有关。后极部穿透研究表明,局部应用后尼普地洛的有效浓度可到达视网膜后极部。